Aducanumab, a recently approved Alzheiemer’s drug with a price tag of about $56,000, could starin Medicaid budgets, costing the program more than $2 billion a year if most beneficiaries switch over to it, according to a new analysis from the Kaiser Family Foundation.
New Alzheimer’s drug could cost Medicaid more than $2 billion
